These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 22630093

  • 41. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
    Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS.
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
    [Abstract] [Full Text] [Related]

  • 42. Occurrence and sensitivity profile of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary hospital in Southern Brazil.
    Rugini CL, Sobottka AM, Fuentefria DB.
    Rev Soc Bras Med Trop; 2015 Apr; 48(6):692-8. PubMed ID: 26676493
    [Abstract] [Full Text] [Related]

  • 43. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW, Trivedi T, Montgomery M, Petrovic DF, Yamaji R, Riley L.
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [Abstract] [Full Text] [Related]

  • 44. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D, Lusa L, Klevišar MN, Terzić S, Pirš M, Premru MM, Strle F.
    Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
    [Abstract] [Full Text] [Related]

  • 45. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ, van Mil AC, Mouton JW.
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Risk factors associated with preoperative fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in liver transplant recipients.
    Bert F, Larroque B, Dondero F, Durand F, Paugam-Burtz C, Belghiti J, Moreau R, Nicolas-Chanoine MH.
    Transpl Infect Dis; 2014 Feb; 16(1):84-9. PubMed ID: 24330161
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
    Lagree M, Bontemps S, Dessein R, Angoulvant F, Madhi F, Martinot A, Cohen R, Dubos F, GPIPGroupe de pathologie infectieuse pédiatrique (Paediatric Infectious Disease Group), France..
    Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
    [Abstract] [Full Text] [Related]

  • 51. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Pagani L, Migliavacca R, Luzzaro F, Giacobone E, Perilli M, Micheletti P, Amicosante G.
    Chemotherapy; 1998 May; 44(6):377-84. PubMed ID: 9755296
    [Abstract] [Full Text] [Related]

  • 52. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
    Anuradha K, Sailaja VV, Umabala P, Satheesh T, Lakshmi V.
    Indian J Med Microbiol; 2007 Jul; 25(3):203-8. PubMed ID: 17901635
    [Abstract] [Full Text] [Related]

  • 53. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
    Banic S.
    APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S, Marre R.
    Infection; 1991 Jan; 19(2):106-9. PubMed ID: 1646771
    [Abstract] [Full Text] [Related]

  • 57. Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.
    Liu PY, Shi ZY, Tung KC, Shyu CL, Chan KW, Liu JW, Wu ZY, Kao CC, Huang YC, Lin CF.
    J Infect Dev Ctries; 2014 Mar 13; 8(3):289-96. PubMed ID: 24619258
    [Abstract] [Full Text] [Related]

  • 58. Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
    Vardi M, Kochavi T, Denekamp Y, Bitterman H.
    Isr Med Assoc J; 2012 Feb 13; 14(2):115-8. PubMed ID: 22693794
    [Abstract] [Full Text] [Related]

  • 59. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
    Morosini MI, García-Castillo M, Coque TM, Valverde A, Novais A, Loza E, Baquero F, Cantón R.
    Antimicrob Agents Chemother; 2006 Aug 13; 50(8):2695-9. PubMed ID: 16870760
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.